Dirk Laurent

Menarini Group (Germany) — Germany

Medicine · Health Sciences

30h-index8.2kcitations90works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(38), Cancer Treatment and Pharmacology(30), Angiogenesis and VEGF in Cancer(20), Cancer, Lipids, and Metabolism(16), Gastric Cancer Management and Outcomes(15)

Publications90 total

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Journal of Clinical Oncology·2022· 628 citedOpen Access
Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
Cancer Research·2022· 17 cited
SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial
Blood·2021· 3 cited
489P MEN1611 in combination with cetuximab: Targeting PIK3CA mutations in RAS-wild-type patient-derived colorectal cancer xenografts
Annals of Oncology·2021· 2 cited
266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
Annals of Oncology·2021· 4 cited
Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.
Journal of Clinical Oncology·2021· 3 cited
SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial
Blood·2020
347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)
Annals of Oncology·2020· 2 cited
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Journal of Clinical Oncology·2020· 164 citedOpen Access
First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
Targeted Oncology·2019· 74 citedOpen Access
Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.
Journal of Clinical Oncology·2018· 16 cited
Abstract CT094: Phase I study of fibroblast growth factor receptor 2 antibody-drug conjugate (FGFR2-ADC) BAY 1187982 in patients with advanced cancer
Cancer Research·2017· 2 cited
Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial
Annals of Oncology·2015Open Access
Abstract 1683: Pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic/toxicodynamic (TK/TD) modeling of preclinical data of FGFR2-ADC (BAY 1187982) to guide dosing in phase 1
Cancer Research·2015· 1 cited
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
The Lancet Oncology·2015· 324 citedOpen Access
Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.
Journal of Clinical Oncology·2015· 26 cited
Abstract 672: Pharmacokinetic and pharmacodynamic (PK/PD) modeling of preclinical data of a novel anti-fibroblast growth factor receptor 2(FGFR2) antibody (BAY 1179470) to guide dosing in Phase 1
Cancer Research·2014· 1 cited
Dynamic Contrast-Enhanced MRI Parameters as Biomarkers for the Effect of Vatalanib in Patients with Non-Small-Cell Lung Cancer
Future Oncology·2014· 10 cited
Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib
Zeitschrift für Gastroenterologie·2013· 3 cited
Time course of regorafenib-associated adverse events in the phase III CORRECT study
Zeitschrift für Gastroenterologie·2013· 3 cited
page 1 of 5Next →

Frequent Co-authors

Eric Van Cutsem(10), Heinz‐Josef Lenz(9), Tanja Trarbach(9), T. Jalava(9), Salvatore Siena(8), Thierry André(8), Eric Masson(8), Alfredo Falcone(7), Marc Ychou(7), Yves Humblet(7), Olivier Bouché(7), Laurent Mineur(7), Antoine Adenis(7), Takayuki Yoshino(7), Richard M. Goldberg(7), Daniel J. Sargent(7), Anne Thomas(7), Bruno Morgan(7), Josep Tabernero(6), Frank Cihon(6)